Free Trial
NASDAQ:VTYX

Ventyx Biosciences Q1 2025 Earnings Report

Ventyx Biosciences logo
$1.76 -0.06 (-3.04%)
As of 11:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ventyx Biosciences EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Ventyx Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ventyx Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Ventyx Biosciences' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ventyx Biosciences Earnings Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Ventyx Biosciences announces seven additional appointments to SAB
See More Ventyx Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ventyx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ventyx Biosciences and other key companies, straight to your email.

About Ventyx Biosciences

Ventyx Biosciences (NASDAQ:VTYX), a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

View Ventyx Biosciences Profile

More Earnings Resources from MarketBeat